The regulatory environment for tirzepatide has changed substantially since the FDA confirmed that the tirzepatide injection drug shortage has been resolved. This development comes as MEDVi, a telehealth platform providing access to GLP-1 weight loss medications, prepares for a significant increase in demand.
MEDVi’s pricing structure for compounded GLP-1 injections starts at $179 for the first month, with refills costing $299 per month. In contrast, the oral option for compounded GLP-1 tablets begins at $249 per month. For comparison, the branded Ozempic injection is priced at a staggering $1,999 per month.
In 2025, MEDVi reported $401 million in sales and is projected to reach $1.8 billion in 2026. Matthew Gallagher, the founder of MEDVi, noted, “Growth was insane,” highlighting the rapid expansion of the company from 300 customers in its first month to 1,300 in the second month.
The company operates under a conditional refund policy for weight loss after five months, with the guarantee requiring a minimum commitment before a refund can be requested. As Gallagher stated, “The evaluating clinician retains the decision to prescribe,” emphasizing the importance of professional oversight in medication management.
MEDVi’s innovative approach combines over a dozen AI tools and strategic partnerships, contributing to its impressive net profit margin of 16.2% in 2025, generating approximately $65 million in profit.
As the healthcare landscape evolves, observers anticipate that MEDVi’s growth trajectory will continue, especially with the resolution of the tirzepatide shortage. The body takes time to acclimate to GLP-1 medication, and MEDVi’s offerings are positioned to meet the increasing demand for effective weight loss solutions.
With its headquarters located in Newark, DE, MEDVi, LLC is poised to become a significant player in the telehealth and weight loss medication market. The company’s strategic initiatives and commitment to patient care are expected to drive further growth in the coming years.